Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$42.02 USD
+0.91 (2.21%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $42.06 +0.04 (0.10%) 5:28 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.02 USD
+0.91 (2.21%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $42.06 +0.04 (0.10%) 5:28 PM ET
4-Sell of 5 4
B Value C Growth D Momentum C VGM
Zacks News
Is Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients
by Zacks Equity Research
Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
by Zacks Equity Research
TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $61.38, moving -0.44% from the previous trading session.
Amphastar Pharmaceuticals (AMPH) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amphastar (AMPH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the second quarter of 2023 are expected to have been driven by the sales of its high-margin pharmaceutical products.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed at $63.25 in the latest trading session, marking a +1.48% move from the prior day.
The Zacks Analyst Blog Highlights Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations
by Zacks Equity Research
Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations are included in this Analyst Blog.
5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.
BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.87, moving +1.07% from the previous trading session.
Here's Why Investors Should Add Encompass Health (EHC) to Portfolio
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano
by Zacks Equity Research
PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.
3 Profitable Stocks Worth Investing in Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.
Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
3 Reasons Growth Investors Will Love Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.